Lungpacer Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $20M

  • Investors
  • 14

Lungpacer General Information

Description

Manufacturer of therapy devices intended for the treatment of diaphragm muscle in critically ill patients who require mechanical ventilation. The company's diaphragm therapy system uses the body's nervous system to send messages to the diaphragm muscle to the source of natural breathing and provides repetitive exercises to rebuild diaphragm muscle strength critical to healthy breathing, helping patients to prevent and reverse muscle-disuse atrophy and maintain diaphragmatic endurance.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Monitoring Equipment
Diagnostic Equipment
Corporate Office
  • 601 West Cordova Street
  • Suite 130
  • Vancouver, British Columbia V6B 1G1
  • Canada
+1 (778) 000-0000

Lungpacer Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lungpacer Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series B1) 06-Apr-2022 $20M 00000 Completed Clinical Trials - General
12. Later Stage VC (Series B) 22-Dec-2020 0000 00000 Completed Clinical Trials - General
11. Later Stage VC (Series 2) 07-Aug-2019 0000 00000 Completed Clinical Trials - General
10. Later Stage VC (Series B) 30-Apr-2019 000.00 000.00 Completed Clinical Trials - General
9. Accelerator/Incubator 01-Jun-2018 000.00 Completed Clinical Trials - General
8. Later Stage VC 01-Jan-2018 000.00 Completed Clinical Trials - General
7. Later Stage VC (Series A) 27-Apr-2017 000.00 000.00 Completed Clinical Trials - General
6. Accelerator/Incubator 26-Nov-2013 00000 Completed Startup
5. Grant 28-Mar-2013 $160K $245K Completed Startup
4. Grant 14-Apr-2010 $170K $245K Completed Startup
To view Lungpacer’s complete valuation and funding history, request access »

Lungpacer Patents

Lungpacer Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230023475-A1 Systems and methods for stimulation Pending 13-Jan-2020 0000000000
EP-4090413-A1 Systems and methods for stimulation Pending 13-Jan-2020 0000000000
EP-4090413-A4 Systems and methods for stimulation Pending 13-Jan-2020 00000000000 0
US-11771900-B2 Circuitry for medical stimulation systems Active 12-Jun-2019 0000000000 000
EP-3983057-A4 Circuitry for medical stimulation systems Pending 12-Jun-2019 A61N1/3601 0
To view Lungpacer’s complete patent history, request access »

Lungpacer Executive Team (6)

Name Title Board Seat Contact Info
Douglas Evans Co-Founder, Chief Executive Officer, President and Board Member
Rosemarie Dhavale Chief Financial Officer
Viral Thakkar Chief Operating Officer
Lesley Fornio Chief Commercial Officer
You’re viewing 4 of 6 executive team members. Get the full list »

Lungpacer Board Members (10)

Name Representing Role Since
Christopher Kiple JD Self Chairman 000 0000
Jan Pensaert Lungpacer Board Member 000 0000
Jose Gordo Self Board Member 000 0000
Joseph Kaufmann 4CGE Board Member 000 0000
Robert Donohue Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Lungpacer Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lungpacer Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
WJFS Family Office Minority 000 0000 000000 0
4CGE Venture Capital Minority 000 0000 000000 0
KCK MedTech Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
MedTech Innovator Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Lungpacer FAQs

  • When was Lungpacer founded?

    Lungpacer was founded in 2009.

  • Who is the founder of Lungpacer?

    Douglas Evans and Andy Hoffer Ph.D are the founders of Lungpacer.

  • Who is the CEO of Lungpacer?

    Douglas Evans is the CEO of Lungpacer.

  • Where is Lungpacer headquartered?

    Lungpacer is headquartered in Vancouver, Canada.

  • What is the size of Lungpacer?

    Lungpacer has 42 total employees.

  • What industry is Lungpacer in?

    Lungpacer’s primary industry is Therapeutic Devices.

  • Is Lungpacer a private or public company?

    Lungpacer is a Private company.

  • What is Lungpacer’s current revenue?

    The current revenue for Lungpacer is 00000.

  • How much funding has Lungpacer raised over time?

    Lungpacer has raised $205M.

  • Who are Lungpacer’s investors?

    WJFS, 4CGE, KCK MedTech, New Enterprise Associates, and MedTech Innovator are 5 of 14 investors who have invested in Lungpacer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »